Pay-for-delay deals disappearing, FTC says

Pay-for-delay deals disappearing, FTC says

Source: 
Biopharma Dive
snippet: 

Legal settlements extending market exclusivity of branded drugs near the end of their patent life rose in 2016, a new report from the Federal Trade Commission found, but almost none of those agreements included a monetary payment from branded drugmakers to generic rivals, commonly known as "pay for delay."